Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care

Objectives: Piperacillin/tazobactam (P/T) is a broad-spectrum β-lactam antibiotic frequently used in outpatient parenteral antimicrobial therapy programs (OPAT). We aim to compare the clinical outcomes of P/T treatment in two models of OPAT care in order to maximize the utilization of health resourc...

Descripción completa

Detalles Bibliográficos
Autores: Lora-Escobar, Santiago J., Herrera-Hidalgo, Laura, Castillo-Fernández, Nerea, Palacios-Baena, Zaira R., Luque-Márquez, Rafael, de Alarcón, Arístides, Gutiérrez Gutiérrez, Belén, Guisado-Gil, Ana Belén, López-Cortés, Luis E.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2025
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/180052
Acceso en línea:https://hdl.handle.net/11441/180052
https://doi.org/10.3390/pharmaceutics17111429
Access Level:acceso abierto
Palabra clave:OPAT
drug delivery
piperacillin/tazobactam
id ES_6971cd1a2f93f2fdc7ed109e0e3334fb
oai_identifier_str oai:idus.us.es:11441/180052
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat careLora-Escobar, Santiago J.Herrera-Hidalgo, LauraCastillo-Fernández, NereaPalacios-Baena, Zaira R.Luque-Márquez, Rafaelde Alarcón, ArístidesGutiérrez Gutiérrez, BelénGuisado-Gil, Ana BelénLópez-Cortés, Luis E.OPATdrug deliverypiperacillin/tazobactamObjectives: Piperacillin/tazobactam (P/T) is a broad-spectrum β-lactam antibiotic frequently used in outpatient parenteral antimicrobial therapy programs (OPAT). We aim to compare the clinical outcomes of P/T treatment in two models of OPAT care in order to maximize the utilization of health resources. Material and methods: We conducted a prospective observational study with retrospective analysis of a cohort of patients treated with P/T delivered every 24 or 48 h in an OPAT program. The primary outcomes were treatment failure during the OPAT episode and 30 day treatment failure. A bivariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Results: Between 2012 and 2022, 247 patients were treated with P/T. Treatment was delivered daily in 176 patients (Group 24) and every two days in 71 patients (Group 48). The rate of treatment failure during OPAT in Group 24 and Group 48 was 12.4% (n = 22) and 5.6% (n = 4), respectively (p = 0.112); and the rate of treatment failure 30 days after OPAT treatment end was 18.2% (n = 32) and 21.1% (n = 15) in Group 24 and Group 48, respectively (p = 0.594). Treatment every 24 or 48 h was not associated with higher treatment failure during OPAT or 30 days after finishing OPAT in either bivariate or multivariate analysis. Conclusions: P/T administration in OPAT programs being replaced every two days is feasible without an increase in treatment failure, relapse, or mortality compared to daily drug replacement. These findings should motivate further research to facilitate the implementation of this novel delivery strategy in OPAT programs.MDPIMedicinaInstituto de Biomedicina de Sevilla (IBIS)2025info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttps://hdl.handle.net/11441/180052https://doi.org/10.3390/pharmaceutics17111429reponame:idUS. Depósito de Investigación de la Universidad de Sevillainstname:Universidad de Sevilla (US)Ingléshttps://www.mdpi.com/1999-4923/17/11/1429info:eu-repo/semantics/openAccessoai:idus.us.es:11441/1800522026-06-17T12:51:07Z
dc.title.none.fl_str_mv Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care
title Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care
spellingShingle Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care
Lora-Escobar, Santiago J.
OPAT
drug delivery
piperacillin/tazobactam
title_short Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care
title_full Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care
title_fullStr Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care
title_full_unstemmed Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care
title_sort Clinical outcomes of piperacillin/tazobactam treatment in outpatient parenteral antimicrobial therapy (OPAT) programs: comparison of two models of opat care
dc.creator.none.fl_str_mv Lora-Escobar, Santiago J.
Herrera-Hidalgo, Laura
Castillo-Fernández, Nerea
Palacios-Baena, Zaira R.
Luque-Márquez, Rafael
de Alarcón, Arístides
Gutiérrez Gutiérrez, Belén
Guisado-Gil, Ana Belén
López-Cortés, Luis E.
author Lora-Escobar, Santiago J.
author_facet Lora-Escobar, Santiago J.
Herrera-Hidalgo, Laura
Castillo-Fernández, Nerea
Palacios-Baena, Zaira R.
Luque-Márquez, Rafael
de Alarcón, Arístides
Gutiérrez Gutiérrez, Belén
Guisado-Gil, Ana Belén
López-Cortés, Luis E.
author_role author
author2 Herrera-Hidalgo, Laura
Castillo-Fernández, Nerea
Palacios-Baena, Zaira R.
Luque-Márquez, Rafael
de Alarcón, Arístides
Gutiérrez Gutiérrez, Belén
Guisado-Gil, Ana Belén
López-Cortés, Luis E.
author2_role author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Medicina
Instituto de Biomedicina de Sevilla (IBIS)
dc.subject.none.fl_str_mv OPAT
drug delivery
piperacillin/tazobactam
topic OPAT
drug delivery
piperacillin/tazobactam
description Objectives: Piperacillin/tazobactam (P/T) is a broad-spectrum β-lactam antibiotic frequently used in outpatient parenteral antimicrobial therapy programs (OPAT). We aim to compare the clinical outcomes of P/T treatment in two models of OPAT care in order to maximize the utilization of health resources. Material and methods: We conducted a prospective observational study with retrospective analysis of a cohort of patients treated with P/T delivered every 24 or 48 h in an OPAT program. The primary outcomes were treatment failure during the OPAT episode and 30 day treatment failure. A bivariate and multivariate logistic regression model was built. A two-sided p < 0.05 was considered statistically significant. Results: Between 2012 and 2022, 247 patients were treated with P/T. Treatment was delivered daily in 176 patients (Group 24) and every two days in 71 patients (Group 48). The rate of treatment failure during OPAT in Group 24 and Group 48 was 12.4% (n = 22) and 5.6% (n = 4), respectively (p = 0.112); and the rate of treatment failure 30 days after OPAT treatment end was 18.2% (n = 32) and 21.1% (n = 15) in Group 24 and Group 48, respectively (p = 0.594). Treatment every 24 or 48 h was not associated with higher treatment failure during OPAT or 30 days after finishing OPAT in either bivariate or multivariate analysis. Conclusions: P/T administration in OPAT programs being replaced every two days is feasible without an increase in treatment failure, relapse, or mortality compared to daily drug replacement. These findings should motivate further research to facilitate the implementation of this novel delivery strategy in OPAT programs.
publishDate 2025
dc.date.none.fl_str_mv 2025
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/11441/180052
https://doi.org/10.3390/pharmaceutics17111429
url https://hdl.handle.net/11441/180052
https://doi.org/10.3390/pharmaceutics17111429
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv https://www.mdpi.com/1999-4923/17/11/1429
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:idUS. Depósito de Investigación de la Universidad de Sevilla
instname:Universidad de Sevilla (US)
instname_str Universidad de Sevilla (US)
reponame_str idUS. Depósito de Investigación de la Universidad de Sevilla
collection idUS. Depósito de Investigación de la Universidad de Sevilla
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869410030799814656
score 15,811543

Similares en LA Referencia